Serum Insulin-Like Growth Factor-I and Tumor Size in Patients with Metastatic Liver Cancer

Mohsen Masoodi; Rahim Aghazadeh; Mohammad Somi; Ahmad Shavakhi; Abbas Shabestari; Mohammad Zali

Hepatitis Monthly

Official Journal of Research Center for Gastroenterology and Liver Diseases

Current Issue Accepted Manuscripts All Issues In Press Articles Search

Journal Information Boards and committees Indexing and Listing Sources Publication Ethics and Malpractice Statement Journal Metrics Support Reviewer and AE Registration Form Contact Us Open Peer Review (OPR)

APC

Authors Guide Submit Manuscript

Serum Insulin-Like Growth Factor-I and Tumor Size in Patients with Metastatic Liver Cancer

Author(s):

Mohsen Masoodi^1,*,

Rahim Aghazadeh²,

Mohammad Hossein Somi³,

Ahmad Shavakhi⁴,

Abbas Arjmand Shabestari²,

Mohammad Reza Zali²

1Department of Internal Medicine, Hormozgan University of Medical Sciences, [email protected], Hormozgan, IR.Iran

2Research Center for Gastroenterology & Liver Diseases (RCGLD), Shaheed Beheshti University of Medical Sciences, Tehran, IR.Iran

3Tabriz Liver and Gastrointestinal Diseases Research Center (LGDRC), Tabriz University of Medical Sciences, Azarbayejan-e-Sharghi, IR.Iran

4Isfahan University of Medical Sciences, Isfahan, IR.Iran

Hepatitis Monthly:Vol. 8, issue 3; 179-183

Published online:Sep 30, 2008

Article type:Research Article

Received:Nov 20, 2007

Accepted:Aug 26, 2008

How to Cite:Masoodi M, Aghazadeh R, Somi M H, Shavakhi A, Shabestari A A, et al. Serum Insulin-Like Growth Factor-I and Tumor Size in Patients with Metastatic Liver Cancer.Hepat Mon.2008;8(3):179-183.

Abstract

Background and Aims: Insulin-like growth factor-I (IGF-1) is a liver-derived humoral factor, which has important anabolic and metabolic actions. Low serum concentrations of IGF-1 have been reported in patients with chronic liver disease, especially cirrhosis and hepatocellular carcinoma and metastatic liver cancer. The aim of our study was to evaluate any possible relationship between intensity of liver metastases on serum IGF-1 concentrations.

Methods: Serum IGF-1 were measured by ELIZA (III) in10 patients with uninodular or multinodular liver metastases and extension |£50% (group A) and 10 patients with multinodular or massive liver metastases and extension > 50% (group B) of liver size without liver failure.

Results: Serum IGF-1 concentration was significantly lower in the more sever metastatic group (group B) than the less sever metastatic group (group A) (121.40 ± 52.08 vs. 210.30 ± 42.59 ng/ml, respectively; P < 0.001).

Conclusions: Our findings suggest that the states of serum IGF-1 levels in patients with metastatic liver cancer may be a helpful finding for determining the severity of metastasis to the liver.

Keywords

IGF-1

Metastatic Liver Cancer

Computed Tomography

Full Text

Full text is available in PDF

Import into EndNote Import into BibTex

Share on

Comments

Number of Comments:0

Metrics

Purchasing Reprints

Copyright Clearance Center (CCC) handles bulk orders for article reprints for Brieflands. To place an order for reprints, please click here ( https://www.copyright.com/landing/reprintsinquiryform/ ). Clicking this link will bring you to a CCC request form where you can provide the details of your order. Once complete, please click the ‘Submit Request’ button and CCC’s Reprints Services team will generate a quote for your review.

Search Relations

Author(s):

Mohsen Masoodi:[PubMed][Scholar]
Rahim Aghazadeh:[PubMed][Scholar]
Mohammad Somi:[PubMed][Scholar]
Ahmad Shavakhi:[PubMed][Scholar]
Abbas Shabestari:[PubMed][Scholar]
Mohammad Zali:[PubMed][Scholar]